Baker Bros. Advisors’s CytomX Therapeutics CTMX Stock Holding History

Baker Bros. Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.7M	Hold	4,975,826	–	–	0.09%	57
2026 Q1	$23.4M	Buy	4,975,826 +725,000	+17%	+$3.68M	0.13%	46
2025 Q4	$18.1M	Hold	4,250,826	–	–	0.11%	55
2025 Q3	$13.6M	Buy	4,250,826 +766,600	+22%	+$1.73M	0.1%	57
2025 Q2	$7.91M	Buy	+3,484,226	New	+$5.62M	0.08%	58
2020 Q2	–	Sell	-20,000	Closed	-$153K	–	115
2020 Q1	$153K	Sell	20,000 -174,377	-90%	-$1.22M	﹤0.01%	110
2019 Q4	$1.61M	Hold	194,377	–	–	0.01%	87
2019 Q3	$1.44M	Hold	194,377	–	–	0.01%	92
2019 Q2	$2.18M	Hold	194,377	–	–	0.01%	83
2019 Q1	$2.09M	Buy	+194,377	New	+$2.87M	0.01%	80

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Baker Bros. Advisors's CTMX Position: Q2 2026 in Review

Baker Bros. Advisors held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 4,975,826 shares worth $18.7M. The position accounts for 0.09% of the portfolio, ranked #57.

Baker Bros. Advisors first reported a position in CTMX in Q1 2019 and has held it in 10 quarters since. The position peaked at $23.4M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Baker Bros. Advisors held 4,975,826 shares of CytomX Therapeutics worth $18.7M as of Q2 2026.
Baker Bros. Advisors left its CytomX Therapeutics share count unchanged in Q2 2026.
CytomX Therapeutics made up 0.09% of Baker Bros. Advisors's portfolio in Q2 2026, its #57 holding.
Baker Bros. Advisors first reported a position in CytomX Therapeutics in Q1 2019 and has held it in 10 quarters since.
Baker Bros. Advisors's CytomX Therapeutics position peaked at $23.4M in Q1 2026.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.